The efficacy and mechanism of Shexiang Tongxin Drop Pills in the treatment of perioperative patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI).

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075069

Enrollment

Unknown

Registered

2023-08-24

Start date

2023-08-31

Completion date

Unknown

Last updated

2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-percutaneous coronary intervention (PCI) for acute myocardial infarction

Interventions

Control group:Conventional treatment + placebo

Observation group:Conventional treatment + Shexiang Tongxin Drop Pills

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age range of 18 to 75 years old, regardless of gender. (2) Meeting the diagnostic criteria for type 1 myocardial infarction. (3) Onset of myocardial ischemic symptoms within 12 hours. (4) Meeting the indications for percutaneous coronary intervention (PCI) and receiving stent placement in the occluded vessel. (5) Willing to participate in this study and sign the informed consent form. 5.Willing to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who received thrombolytic therapy before surgery. (2) Patients with cardiogenic shock, cardiac rupture, ventricular septal perforation, or suspected aortic dissection. (3) Patients who underwent cardiopulmonary resuscitation or had an implantation of a cardiac assist device (such as IABP) in the past month. (4) Patients with severe heart failure and known ejection fraction <30%, or New York Heart Association (NYHA) class III or above, or Killip class 3 or above. (5) Patients with severe arrhythmias (fast atrial fibrillation/flutter, ventricular tachycardia/fibrillation, second-degree type II atrioventricular block or above). (6) Patients with severe infection. (7) Patients with moderate to severe anemia (HGB<90g/L). (8) Patients with active bleeding or a tendency towards bleeding. (9) Patients with severe primary diseases involving the liver, kidney, hematopoietic system, or malignant tumors. (10) Patients with allergies or known allergy to the investigational drugs. (11) Patients with significant mental disorders or difficulty in compliance. (12) Pregnant or lactating women. (13) Patients who are already enrolled in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Cardiac biomarkers.;	—

Secondary

Measure	Time frame
Chest tightness, chest pain;Seattle Angina Scale;MACE incidence rate;Safety evaluation;	—

Countries

china

Contacts

Public ContactMeng Li

Beijing University of Chinese Medicine Dongzhimen Hospital

1092632654@qq.com+86 152 0132 8277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026